Genetically targeted clinical trials in parkinson’s disease : Learning from the successes made in oncology
(2021) In Genes 12(10).- Abstract
Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in... (More)
Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in Parkinson’s disease and the potential of further implementing genetics, biomarkers and smart clinical trial designs in this disease area.
(Less)
- author
- Sjögren, Magnus ; Huttunen, Henri J. ; Svenningsson, Per and Widner, Håkan LU
- publishing date
- 2021-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Clinical trials, Genetic targets, Neurodegenerative disorders, Oncology, Parkinson’s disease, Precision medicine
- in
- Genes
- volume
- 12
- issue
- 10
- article number
- 1529
- publisher
- MDPI AG
- external identifiers
-
- scopus:85116142618
- pmid:34680924
- ISSN
- 2073-4425
- DOI
- 10.3390/genes12101529
- language
- English
- LU publication?
- no
- additional info
- Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- id
- 058594df-6639-4455-95d8-096142452b91
- date added to LUP
- 2021-10-20 15:10:59
- date last changed
- 2024-06-15 18:30:28
@article{058594df-6639-4455-95d8-096142452b91,
abstract = {{<p>Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in Parkinson’s disease and the potential of further implementing genetics, biomarkers and smart clinical trial designs in this disease area.</p>}},
author = {{Sjögren, Magnus and Huttunen, Henri J. and Svenningsson, Per and Widner, Håkan}},
issn = {{2073-4425}},
keywords = {{Clinical trials; Genetic targets; Neurodegenerative disorders; Oncology; Parkinson’s disease; Precision medicine}},
language = {{eng}},
number = {{10}},
publisher = {{MDPI AG}},
series = {{Genes}},
title = {{Genetically targeted clinical trials in parkinson’s disease : Learning from the successes made in oncology}},
url = {{http://dx.doi.org/10.3390/genes12101529}},
doi = {{10.3390/genes12101529}},
volume = {{12}},
year = {{2021}},
}